ALKBH5 Suppresses Malignancy of Hepatocellular Carcinoma Via MA-guided Epigenetic Inhibition of LYPD1

Overview

Journal Mol Cancer

Publisher Biomed Central

Specialties Molecular Biology
Oncology

Date 2020 Aug 11

PMID 32772918

Citations 143

Authors

Yunhao Chen

Yanchun Zhao

Junru Chen

Chuanhui Peng

Yanpeng Zhang

Rongliang Tong

Qiyang Cheng

Beng Yang

Xiaode Feng

Yuejie Lu

Haiyang Xie

Lin Zhou

Jian Wu

Shusen Zheng

Affiliations

Soon will be listed here.

Abstract

Background: N6-methyladenosine (mA) modification is an emerging layer of epigenetic regulation which is widely implicated in the tumorigenicity of hepatocellular carcinoma (HCC), offering a novel perspective for investigating molecular pathogenesis of this disease. The role of AlkB homolog 5 (ALKBH5), one of the mA demethylases, has not been fully explored in HCC. Here we clarify the biological profile and potential mechanisms of ALKBH5 in HCC.

Methods: Expression of ALKBH5 and its correlation with clinicopathological characteristics of HCC were evaluated using tissue microarrays and online datasets. And biological effects of ALKBH5 in HCC were determined in vitro and in vivo. Subsequently, methylated RNA immunoprecipitation sequencing (MeRIP-seq) combined with RNA sequencing (RNA-seq), and following mA dot blot, MeRIP-qPCR, RIP-qPCR or dual luciferase reporter assays were employed to screen and validate the candidate targets of ALKBH5.

Results: We demonstrated that ALKBH5 was down-regulated in HCC, and decreased ALKBH5 expression was an independent prognostic factor of worse survival in HCC patients. Functionally, ALKBH5 suppressed the proliferation and invasion capabilities of HCC cells in vitro and in vivo. Mechanistically, ALKBH5-mediated mA demethylation led to a post-transcriptional inhibition of LY6/PLAUR Domain Containing 1 (LYPD1), which could be recognized and stabilized by the mA effector IGF2BP1. In addition, we identified that LYPD1 induced oncogenic behaviors of tumors in contrast to ALKBH5. Dysregulation of ALKBH5/LYPD1 axis impelled the progression of HCC.

Conclusion: Our study reveals that ALKBH5, characterized as a tumor suppressor, attenuates the expression of LYPD1 via an mA-dependent manner in HCC cells. Our findings enrich the landscape of mA-modulated tumor malignancy, and provide new insights into potential biomarkers and therapeutic targets of HCC treatment.

Citing Articles

RNA Modification in Metabolism.

Liu Y, Sun Z, Gui D, Zhao Y, Xu Y MedComm (2020). 2025; 6(3):e70135.

PMID: 40066222 PMC: 11892166. DOI: 10.1002/mco2.70135.

m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy.

Liu F, Liu Q, Li X, Wang Y, Cao R, Zhang S Front Immunol. 2025; 16:1538658.

PMID: 40034695 PMC: 11873077. DOI: 10.3389/fimmu.2025.1538658.

m6A RNA methylation: a pivotal regulator of tumor immunity and a promising target for cancer immunotherapy.

Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X J Transl Med. 2025; 23(1):245.

PMID: 40022120 PMC: 11871626. DOI: 10.1186/s12967-025-06221-y.

The RNA M5C methyltransferase NSUN2 promotes progression of hepatocellular carcinoma by enhancing PKM2-mediated glycolysis.

Qi Q, Zhong R, Huang Y, Tang Y, Zhang X, Liu C Cell Death Dis. 2025; 16(1):82.

PMID: 39924557 PMC: 11808121. DOI: 10.1038/s41419-025-07414-5.

ALKBH5, an m6A demethylase, attenuates tumor growth and inhibits metastasis in papillary thyroid carcinoma.

Zhuang Y, Cai Q, Hu X, Huang H Sci Rep. 2025; 15(1):1514.

PMID: 39789120 PMC: 11718269. DOI: 10.1038/s41598-024-84352-w.

References

Liu X, Liu J, Xiao W, Zeng Q, Bo H, Zhu Y . SIRT1 Regulates N -Methyladenosine RNA Modification in Hepatocarcinogenesis by Inducing RANBP2-Dependent FTO SUMOylation. Hepatology. 2020; 72(6):2029-2050. DOI: 10.1002/hep.31222. View

Rebouissou S, Nault J . Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020; 72(2):215-229. DOI: 10.1016/j.jhep.2019.08.017. View

Huang H, Weng H, Chen J . mA Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer. Cancer Cell. 2020; 37(3):270-288. PMC: 7141420. DOI: 10.1016/j.ccell.2020.02.004. View

Jin D, Guo J, Wu Y, Yang L, Wang X, Du J . mA demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC. Mol Cancer. 2020; 19(1):40. PMC: 7045432. DOI: 10.1186/s12943-020-01161-1. View

Yu D, Fan W, Liu G, Nguy V, Chatterton J, Long S . PHTS, a novel putative tumor suppressor, is involved in the transformation reversion of HeLaHF cells independently of the p53 pathway. Exp Cell Res. 2006; 312(6):865-76. DOI: 10.1016/j.yexcr.2005.12.006. View

Zhao Z, Meng J, Su R, Zhang J, Chen J, Ma X . Epitranscriptomics in liver disease: Basic concepts and therapeutic potential. J Hepatol. 2020; 73(3):664-679. DOI: 10.1016/j.jhep.2020.04.009. View

Etienne-Manneville S, Hall A . Rho GTPases in cell biology. Nature. 2002; 420(6916):629-35. DOI: 10.1038/nature01148. View

Deng X, Su R, Weng H, Huang H, Li Z, Chen J . RNA N-methyladenosine modification in cancers: current status and perspectives. Cell Res. 2018; 28(5):507-517. PMC: 5951805. DOI: 10.1038/s41422-018-0034-6. View

Wang Q, Chen C, Ding Q, Zhao Y, Wang Z, Chen J . METTL3-mediated mA modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2019; 69(7):1193-1205. DOI: 10.1136/gutjnl-2019-319639. View

10.

Hu B, Wang X, Gu X, Zou C, Gao Z, Zhang H . N-methyladenosine (mA) RNA modification in gastrointestinal tract cancers: roles, mechanisms, and applications. Mol Cancer. 2019; 18(1):178. PMC: 6898962. DOI: 10.1186/s12943-019-1099-7. View

11.

Zheng Q, Hou J, Zhou Y, Li Z, Cao X . The RNA helicase DDX46 inhibits innate immunity by entrapping mA-demethylated antiviral transcripts in the nucleus. Nat Immunol. 2017; 18(10):1094-1103. DOI: 10.1038/ni.3830. View

12.

Hou J, Zhang H, Liu J, Zhao Z, Wang J, Lu Z . YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Mol Cancer. 2019; 18(1):163. PMC: 6859620. DOI: 10.1186/s12943-019-1082-3. View

13.

Chen M, Wong C . The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis. Mol Cancer. 2020; 19(1):44. PMC: 7047367. DOI: 10.1186/s12943-020-01172-y. View

14.

Huang H, Weng H, Sun W, Qin X, Shi H, Wu H . Recognition of RNA N-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018; 20(3):285-295. PMC: 5826585. DOI: 10.1038/s41556-018-0045-z. View

15.

Ma J, Yang F, Zhou C, Liu F, Yuan J, Wang F . METTL14 suppresses the metastatic potential of hepatocellular carcinoma by modulating N -methyladenosine-dependent primary MicroRNA processing. Hepatology. 2016; 65(2):529-543. DOI: 10.1002/hep.28885. View

16.

Zhang C, Samanta D, Lu H, Bullen J, Zhang H, Chen I . Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m⁶A-demethylation of NANOG mRNA. Proc Natl Acad Sci U S A. 2016; 113(14):E2047-56. PMC: 4833258. DOI: 10.1073/pnas.1602883113. View

17.

Li J, Zhu L, Shi Y, Liu J, Lin L, Chen X . m6A demethylase FTO promotes hepatocellular carcinoma tumorigenesis via mediating PKM2 demethylation. Am J Transl Res. 2019; 11(9):6084-6092. PMC: 6789218. View

18.

Dessaud E, Salaun D, Gayet O, Chabbert M, Delapeyriere O . Identification of lynx2, a novel member of the ly-6/neurotoxin superfamily, expressed in neuronal subpopulations during mouse development. Mol Cell Neurosci. 2005; 31(2):232-42. DOI: 10.1016/j.mcn.2005.09.010. View

19.

Trapnell C, Hendrickson D, Sauvageau M, Goff L, Rinn J, Pachter L . Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat Biotechnol. 2012; 31(1):46-53. PMC: 3869392. DOI: 10.1038/nbt.2450. View

20.

Trapnell C, Williams B, Pertea G, Mortazavi A, Kwan G, van Baren M . Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010; 28(5):511-5. PMC: 3146043. DOI: 10.1038/nbt.1621. View